Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

Table 5 Changes in lipid parameters in all patients and patients grouped according to treatment order

Parameter	n	Baseline	LOCF	Change	%	p-value
LDL-C
Total	249	136.2 ± 36.6	112.5 ± 27.4	−23.7 ± 36.1	−17.4	<0.001
EZE + BEZA	67	120.0 ± 31.1	110.5 ± 22.9	−9.4 ± 31.7	−7.8	0.017
BEZA + EZE	99	143.6 ± 32.4	114.6 ± 25.1	−29.1 ± 29.0	−20.3	<0.001
BEZA & EZE	83	140.6 ± 41.5	111.6 ± 33.0	−29.0 ± 43.5	−20.6	<0.001
HDL-C
Total	445	52.1 ± 14.2	56.7 ± 14.3	4.6 ± 11.2	8.8	<0.001
EZE + BEZA	138	52.5 ± 14.4	58.2 ± 14.8	5.7 ± 10.3	10.9	<0.001
BEZA + EZE	164	53.0 ± 15.2	55.4 ± 14.3	2.4 ± 12.0	4.5	0.012
BEZA & EZE	143	50.6 ± 12.6	56.9 ± 13.7	6.3 ± 10.9	12.5	<0.001
TG
Total	483	266.6 ± 210.1	158.6 ± 112.2	−108.0 ± 181.3	−40.5	<0.001
EZE + BEZA	143	274.9 ± 169.0	147.6 ± 77.8	−127.3 ± 149.7	−46.3	<0.001
BEZA + EZE	183	244.0 ± 193.0	166.0 ± 125.0	−78.0 ± 193.7	−32.0	<0.001
BEZA & EZE	157	285.4 ± 256.7	160.1 ± 122.2	−125.2 ± 189.0	−43.9	<0.001
Non-HDL-C
Total	293	183.5 ± 41.8	143.8 ± 32.4	−39.6 ± 40.9	−21.6	<0.001
EZE + BEZA	85	168.2 ± 33.2	142.7 ± 30.0	−25.5 ± 33.2	−15.2	<0.001
BEZA + EZE	112	187.3 ± 43.1	144.1 ± 29.2	−43.1 ± 39.2	−23.0	<0.001
BEZA & EZE	96	192.5 ± 43.7	144.5 ± 38.0	−48.0 ± 46.0	−24.9	<0.001

Data are expressed as mean ± standard deviation. “Change” indicates the change from baseline to the LOCF value. “%” indicates rate of change from baseline to the LOCF. The paired t test was used to examine the significance of within-group changes. LDL-C was estimated using the Friedewald formula. LOCF: last observation carried forward; EZE + BEZA: patients who were already taking ezetimibe and then added bezafibrate at the start of the study; BEZA + EZE: patients who were already taking bezafibrate and then added ezetimibe at the start of the study; BEZA & EZE: patients who started bezafibrate and ezetimibe concurrently.

ISSN: 1475-2840